Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Taiho Ventures
BioCentury | Aug 15, 2024
Finance
Venture Report: Halda bringing RIPTACs into clinic with crossover round
Plus: Abata draws strategic investment from BMS as it preps first human study in multiple sclerosis
BioCentury | Apr 18, 2024
Finance
Venture report: Metsera’s $290M launch, Regeneron’s new VC fund
Plus fundings for Asher, Pathios, Outrun and Theolytics
BioCentury | Sep 21, 2023
Emerging Company Profile
hC Bio: restoring protein function with tRNA therapies
Its sights set on cancer and rare diseases, Boston-based hC Bioscience hopes to take its first engineered tRNA therapy into the clinic next year
BioCentury | Jul 21, 2023
Management Tracks
Ann Lee-Karlon named CEO of EpiBiologics
Plus: Haas becomes CEO at LimmaTech, and updates from Sagimet, Agenus, Triumvira and Passage Bio
BioCentury | Feb 7, 2023
Product Development
Feb. 6 Quick Takes: Idorsia falls on Phase III miss
Plus: Arrowhead awaits J&J’s decision on HBV partnership and updates from Dragonfly, Sage-Biogen, IgGenix, Certa and more
BioCentury | Dec 15, 2022
Finance
Dec. 14 Quick Takes: Alpha-9 lands $75M for radiopharmaceutical pipeline
Plus: Avidity gains 55% on antibody-oligo conjugate data, and updates from Storm, Avidity, Kymera, Icosavax and more
BioCentury | Nov 8, 2022
Deals
Nov. 7 Quick Takes: Viatris buying Oyster Point a year after dry eye approval
Plus Verve falls on clinical hold and updates from GSK, Beam, Veru, hC
BioCentury | Oct 27, 2022
Emerging Company Profile
Normunity: coaxing T cells to enter tumors
Canaan-backed start-up is tapping T cell mobility, infiltration mechanisms to turn cold tumors hot
BioCentury | Jun 15, 2022
Market Access
June 14 Quick Takes: ICER weighs in on Amylyx’s ALS treatment
Plus EQRx’s first regulatory submission, WHO to discuss monkeypox status and updates from PureTech, Tilt and more
BioCentury | Jun 3, 2022
Deals
June 2 Quick Takes: BMS, Immatics expand partnership to allogeneic T cells
Plus Transition’s $50M A round, Centessa’s killed kidney program and updates from Centessa, Aeglea, Immunic and more
Items per page:
1 - 10 of 56